Published in the Red Journal, this guideline document from PTCOG Ocular Group summarized the current state of proton ocular treatment with available clinical evidence of proton radiation for uveal melanoma, conjunctival tumors, choroidal metastases, hemangiomas, other vascular tumors, macular degeneration, and retinoblastomas, as primary, salvage, or adjuvant therapy. This document also provides detailed practice guidance for target volume definition, treatment planning, treatment delivery and post treatment care. The document points out that the most important developments include improving imaging modalities, TPS, QA techniques, and vendor options for low and high-energy beamlines, minimizing parameters such as lateral penumbra and distal fall-o9 and improving dose homogeneity and dose-rate.